液滴数字PCR检测血浆游离BRAF V600E在黑色素瘤皮肤监测中的意义
该研究用液滴数字PCR定量146例无黑色素瘤皮肤筛查者、26例III期和7例IV期BRAF突变黑色素瘤患者及32例无病生存≥3年患者血浆游离BRAF V600E。无黑色素瘤者水平更低。
要点
- 血浆游离BRAF V600E在晚期黑色素瘤患者中检出率较高,早期或微转移者不敏感。
- 无黑色素瘤个体中痣数量多或存在非典型痣不影响cfBRAF V600E检出。
核心结论
- 痣相关因素不影响无黑色素瘤个体血浆cfBRAF V600E的检测。
- 血浆cfBRAF V600E定量在黑色素瘤患者中具有临床诊断价值。
- cfBRAF V600E是可用于皮肤监测项目的稳健可靠生物标志物。
研究设计与样本
- 研究采用液滴数字PCR定量血浆cfBRAF V600E。
- 样本包括146例无黑色素瘤的连续皮肤筛查者、26例III期和7例IV期BRAF突变黑色素瘤患者、32例无病生存≥3年的黑色素瘤患者。
主要发现
- 无病生存的黑色素瘤患者中未检出cfBRAF V600E突变。
- 无黑色素瘤个体的cfBRAF V600E水平低于黑色素瘤患者。
- 无黑色素瘤个体中52%痣数量多(>50),49%有临床非典型痣。
临床怎么用
- 血浆cfBRAF V600E定量可用于黑色素瘤患者的监测和诊断辅助。
- 在皮肤监测项目中,痣相关因素不影响cfBRAF V600E检测结果的解读。
- 该标志物对晚期黑色素瘤有效,但对早期或微转移患者不敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi. Analysis of the cell-free BRAF c.1799T>A, p.V600E mutation (cfBRAFV 600E ) in plasma has emerged as a biomarker for monitoring prognosis and treatment response in patients with melanoma. OBJECTIVES: To quantify cfBRAFV 600E levels in plasma from patients with melanoma and from patients without melanoma undergoing regular follow-up of their melanocytic lesions, in order to assess the clinical significance of the test. METHODS: We quantified cfBRAFV 600E by droplet digital polymerase chain reaction in plasma from 146 patients without melanoma undergoing continuous dermatological screening, from 26 stage III and seven stage IV patients with BRAF-mutant melanoma, and from 32 patients with melanoma who were free of disease for 3 or more years. RESULTS: Among disease-free patients and individuals without melanoma, 52% presented a high naevus count (> 50) and 49% had clinically atypical naevi. cfBRAFV 600E was detected in 71% of patients with stage IV melanoma and 15% with stage III, and in 1·4% of individuals without melanoma. No cfBRAFV 600E mutation was detected in disease-free patients with melanoma. Individuals without melanoma had lower cfBRAFV 600E levels than patients with melanoma. We established a variant allelic frequency of 0·26% or 5 copies mL-1 of cfBRAFV 600E as the optimal cutoff value for identifying patients with melanoma with > 99% specificity. CONCLUSIONS: This study suggests that naevus-related factors do not influence the detection of cfBRAFV 600E in individuals without melanoma, and supports the clinical diagnostic value of plasma cfBRAFV 600E quantification in patients with melanoma. What's already known about this topic? The analysis of the BRAF c.1799T>A (p.V600E) mutation in cell-free (cf)DNA has emerged as a potential biomarker for monitoring prognosis and treatment response in patients with metastatic BRAFV600E melanoma. The BRAFV600E alteration is a common genetic alteration found in benign proliferations such as melanocytic naevi. No information exists about the impact of the number of common acquired naevi or the presence of clinically atypical naevi in cfBRAFV600E detection in an individual. What does this study add? The cfBRAFV600E mutation is detected in plasma from a reduced number of individuals without melanoma undergoing continuous dermatological follow-up. A high number of naevi or the presence of clinically atypical naevi are factors that do not influence cfBRAFV600E detection in an individual. Both total cfBRAF concentration and cfBRAFV600E frequency are effective biomarkers in patients with advanced melanoma but not in patients at early stages or with micrometastases. What is the translational message? Detection of cfBRAFV600E in an individual is not influenced by naevus-related factors. cfBRAFV600E is a robust and reliable biomarker that can be used in dermatological surveillance programmes.
引用
- Calbet-Llopart N, Potrony M, Tell-Martí G, et al. Detection of cell-free circulating BRAFV 600E by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance. Br J Dermatol. 2019. PMID: 31102256. doi:10.1111/bjd.18147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。